Crinetics Pharmaceuticals
Trade Crinetics Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CRNX
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly.
CRNX Key Statistics
Stock Snapshot
As of today, Crinetics Pharmaceuticals(CRNX) shares are valued at $41.43. The company's market cap stands at 4.09B, with a P/E ratio of -10.58.
On 2025-11-07, Crinetics Pharmaceuticals(CRNX) stock moved within a range of $39.63 to $43.89. With shares now at $41.43, the stock is trading +4.5% above its intraday low and -5.6% below the session's peak.
Trading activity shows a volume of 2.11M, compared to an average daily volume of 1.26M.
Over the past 52 weeks, Crinetics Pharmaceuticals(CRNX) stock has traded between a high of $62.53 and a low of $24.10.
Over the past 52 weeks, Crinetics Pharmaceuticals(CRNX) stock has traded between a high of $62.53 and a low of $24.10.
CRNX News
Reports Q3 revenue $143,00, consensus $394,000. “September 25, 2025 was a historic day for Crinetics (CRNX) with the approval of Palsonify for the treatment of...